UNSPSC 51283603: Rifapentine

This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJM390A33U. European Medicines Agency schedules Rifapentine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10311MIG. Rifapentine generally arises in the molecular formula C47H64N4O12.

The term RIFAPENTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) RIFAPENTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifapentine under HS 29419000 and SITC 54139. As of Q4 2014, RIFAPENTINE remains the US FDA Preferred Term for this commodity. Rifapentine bears US NLM identifiers UMLS ID C0073372 and NCI Concept Code C66516.

UNSPSC 51283603 Rifapentine, a Commodity code, nominally designates a specific tuberculosis treatment drug, but recent state and local procurement activity under this code shows little direct connection to rifapentine itself. The code appears in solicitations for naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription programs—none of which center on rifapentine procurement. State and local issuing bodies using this code include county health departments (Seminole County, Florida), municipal fire departments and purchasing offices (City of Tampa), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The mismatch between the code's nominal scope and the actual work being solicited suggests either mis-coding in the state and local procurement systems or a taxonomic artifact where broader pharmaceutical and medical-supply categories have been tagged with a specific-drug code identifier.

Recent opportunities posted between January and June 2026 include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023—note the discrepancy with the June 2026 posting date), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division (estimated contract value $700,000, due March 13, 2026, with an SLBE set-aside and 5 percent bid discount), the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (due March 26, 2026, with awards effective July 1, 2026), and the Texas HHS Commission RFI on direct-to-manufacturer prescription programs (posted April 3, 2026). Geographic activity centers on Florida, Texas, Minnesota, and Oregon, reflecting both state-level demand and multi-jurisdictional cooperative purchasing networks. Because recent opportunities tagged to this code do not meaningfully align with rifapentine as a discrete product line, business development professionals should verify the actual pharmaceutical or medical-supply category under which their target customer jurisdictions place drug procurement before pursuing opportunities coded to UNSPSC 51283603.